Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00082894" target="_blank" >RIV/00216224:14110/15:00082894 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1111/cei.12459" target="_blank" >http://dx.doi.org/10.1111/cei.12459</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/cei.12459" target="_blank" >10.1111/cei.12459</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis
Popis výsledku v původním jazyce
Common variable immunodeficiency (CVID) encompasses a heterogeneous group of antibody deficiencies characterized by susceptibility to recurrent infections and sequelae, including bronchiectasis. We investigated the relevance of the lectin complement pathway in CVID patients by analysing ficolin-2 and ficolin-3 serum levels and genotyping single nucleotide polymorphisms (SNPs) in the FCN2 and FCN3 genes. Our results show that ficolin-2 levels in CVID patients are significantly lower (P<00001) than incontrols. The lowest ficolin-2 levels are found in CVID patients with bronchiectasis (P=00004) and autoimmunity (P=004). Although serum levels of ficolin-3 were similar in CVID patients and controls, CVID patients with bronchiectasis again showed lower levels when compared to controls (P=00001). Analysis of single nucleotide polymorphisms in the FCN2 gene confirmed known influences on ficolin-2 serum levels, but did not support a genetic basis for the observed ficolin-2 deficiency in CVI
Název v anglickém jazyce
Low ficolin-2 levels in common variable immunodeficiency patients with bronchiectasis
Popis výsledku anglicky
Common variable immunodeficiency (CVID) encompasses a heterogeneous group of antibody deficiencies characterized by susceptibility to recurrent infections and sequelae, including bronchiectasis. We investigated the relevance of the lectin complement pathway in CVID patients by analysing ficolin-2 and ficolin-3 serum levels and genotyping single nucleotide polymorphisms (SNPs) in the FCN2 and FCN3 genes. Our results show that ficolin-2 levels in CVID patients are significantly lower (P<00001) than incontrols. The lowest ficolin-2 levels are found in CVID patients with bronchiectasis (P=00004) and autoimmunity (P=004). Although serum levels of ficolin-3 were similar in CVID patients and controls, CVID patients with bronchiectasis again showed lower levels when compared to controls (P=00001). Analysis of single nucleotide polymorphisms in the FCN2 gene confirmed known influences on ficolin-2 serum levels, but did not support a genetic basis for the observed ficolin-2 deficiency in CVI
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
EC - Imunologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Clinical and Experimental Immunology
ISSN
0009-9104
e-ISSN
—
Svazek periodika
179
Číslo periodika v rámci svazku
2
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
9
Strana od-do
256-264
Kód UT WoS článku
000347233800012
EID výsledku v databázi Scopus
—